Arbutus Biopharma (NASDAQ: ABUS) reported Q2 EPS of $0.01, $0.05 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $10.74 million versus the consensus estimate of $1.61 million.

For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.